Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

In Morbidity and Mortality Weekly Report, three new studies describe increased infections of parvovirus B19 detected in US ...

Tebentafusp – sold under the brand name Kimmtrak – is the first treatment of its kind for uveal melanoma, which develops from ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

BOSTON (AP) — A judge has set a date of Oct. 20, 2025, for the trial of a Massachusetts man charged with killing his wife.

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. Type 1 diabetes develops when the body destroys its own insulin-producing cells.

Join Lalla Hirayama in her call to action as she delves into her health journey, tackling the stigma around Pap smears and ...

Something is blooming above the Parnassus Heights campus – where scientists are accelerating research to treat the world’s ...

This study provides valuable insights into the differential impact of intrinsic and synaptic conductances on circuit robustness, emphasizing intrinsic plasticity as a crucial but often overlooked ...